Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. SNWV
SNWV logo

SNWV Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy SANUWAVE Health Inc (SNWV) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
10.820
1 Day change
3.05%
52 Week Range
46.590
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

SNWV is not a good buy right now for a beginner long-term investor with $50,000-$100,000 who wants a direct entry without waiting. The stock is near short-term resistance and lacks strong buy signals, fresh catalysts, or supportive fundamental data. While momentum is improving, the broader trend remains mixed and not strong enough to justify an immediate buy.

Technical Analysis

Technically, SNWV is mixed but not a clean buy. MACD is positive and expanding, which supports short-term momentum. However, RSI_6 at 57.16 is neutral, so the stock is not oversold or clearly accelerating. The moving averages are bearish with SMA_200 > SMA_20 > SMA_5, which signals the longer-term trend is still weak. Price at 10.66 is just above R1 at 10.529 and close to the recent resistance area, while pivot support is 9.23. The stock trend model suggests modest upside over the next week and month, but not enough to override the bearish longer-term structure.

Positive Catalysts

  • ["MACD histogram is positive and expanding", "Short-term modeled probability suggests mild upside over the next week and month", "Price is holding above the pivot level"]

Neutral/Negative Catalysts

  • ["No news in the recent week", "No signal from AI Stock Picker", "No recent SwingMax entry signal", "Bearish moving average structure (SMA_200 > SMA_20 > SMA_5)", "No significant hedge fund or insider buying trends", "No recent congress trading data", "No valuation data or usable financial snapshot provided"]

Financial Performance

No usable latest-quarter financial snapshot was available, so recent revenue, earnings, and growth trends cannot be assessed. The latest quarter season is not provided in the data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no recent Wall Street upgrade/downgrade trend to report. Based on the available information, analysts' pros and cons view cannot be confirmed, but the absence of supportive updates is a negative sign.

Wall Street analysts forecast SNWV stock price to rise
2 Analyst Rating
Wall Street analysts forecast SNWV stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 10.500
sliders
Low
53
Averages
54
High
55
Current: 10.500
sliders
Low
53
Averages
54
High
55
Roth Capital
Kyle Bauser
Buy
downgrade
$53 -> $47
AI Analysis
2026-03-27
Reason
Roth Capital
Kyle Bauser
Price Target
$53 -> $47
AI Analysis
2026-03-27
downgrade
Buy
Reason
Roth Capital analyst Kyle Bauser lowered the firm's price target on Sanuwave Health to $47 from $53 and keeps a Buy rating on the shares. Despite an FY26 revenue outlook of $51M-55M that missed consensus of $58.0M, the firm views the outlook as "favorable given the disruption from skin sub reimbursement changes," the analyst tells investors in a post-earnings note.
Northland
Carl Byrnes
Outperform
initiated
$55
2026-01-05
Reason
Northland
Carl Byrnes
Price Target
$55
2026-01-05
initiated
Outperform
Reason
Northland analyst Carl Byrnes named Sanuwave Health as a 2026 Top Pick with an Outperform rating and $55 price target. The company's UltraMist installed base was up 55% year-over-year ending Q3, notes the analyst, who believes recent CMS PFS/OPPS reimbursement changes for skin substitutes should act as a demand catalyst for UltraMist as physicians seek incremental, procedure-based revenue.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for SNWV
Unlock Now

People Also Watch